Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations. Sivina M, Kim E, Wierda WG, Ferrajoli A, et al. Blood 2021;138:2589-2592.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sivina M, Kim E, Wierda WG, Ferrajoli A, et al. Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations. Blood 2021;138:2589-2592.
PMID: 34521099